Colorectal Cancer

IntegraGen is developing a predictive test based on the biomarker miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR (epidermal growth factor receptor) monoclonal antibody therapy response in wild-type KRAS patients with metastatic colorectal cancer.

Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. Incidence rates are substantially higher in men. 20% to 25% of CRC have metastases at time of diagnosis and 40% develop metastases following initial surgical treatment of CRC.